Denigration: The Paris Court of Appeal largely upholds the condemnation by the French Competition Authority of a pharmaceutical company for an abuse of its dominant position having delayed and then limited generic entry (Janssen-Cilag, Johnson & Johnson)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. By a judgment of 11 July 2019, the Paris Court of Appeal largely confirmed the decision of the Competition Authority ('the Authority') No 17-D-25 of 20 December 2017 which had sanctioned the Janssen-Cilag laboratory, and its parent company Johnson & Johnson, for first delaying and then limiting the development of generics of its drug, Durogesic (Dec. No 17-D-25 of 20 December 2017 relating to practices implemented in the fentanyl transdermal device sector, comm. A. Wachsmann, Concurrences No. 2-2018, p. 84). However, the Paris Court of Appeal reduced the amount of the penalty from 25 million euros to 21 million euros. Durogesic is a powerful opioid